Treatment With Tildren®

(tiludronate disodium)

Tildren® (tiludronate disodium) will be administered to your horse through an intravenous infusion. It is administered over a 90-minute period.

Tildren® is most effective when used in conjunction with corrective farriery and a controlled exercise program. Visit with your veterinarian to learn more about management and care after Tildren® has been given.

Product Safety

In a controlled 6-month open use field study1, Tildren® (tiludronate disodium) was evaluated under strict conditions. Horses were observed for four hours following infusion and adverse events were recorded.

treatment horse bm

Dosing and Administration

Tildren® is administered through a single intravenous infusion of 1mg/kg (0.45mg/lb) in 0.9% Sodium Chloride, and is given slowly and evenly over 90 minutes. Of the administered dose, 30-50% of the tiludronate disodium distributes to the bone within 12 hours of dosing.

Bone concentrations are higher than plasma concentrations as early as 12 hours post-administration. The drug is slowly, but continuously, released in relation to the bone remodeling process and concentrations are still present at 6 months, but lower than at 3 months, in the bone.

treatment graph bm

Do not use in horses with impaired renal function or with a history of renal disease. NSAIDs should not be used concurrently with TILDREN® . Concurrent use of NSAIDs with TILDREN® may increase the risk of renal toxicity and acute renal failure. Horses should be observed closely for 4 hours post-infusion for the development of clinical signs consistent with colic or other adverse reactions.

Caution should be used when administering TILDREN® to horses with conditions affecting mineral or electrolyte homeostasis (e.g. HYPP, hypocalcemia) and conditions which may be exacerbated by hypocalcemia (e.g. cardiac disease). The safe use of TILDREN® has not been evaluated in horses less than 4 years of age, in pregnant or lactating mares, or in breeding horses. See package insert for full prescribing information.